Nucala Approval History
FDA Approved: Yes (First approved November 4, 2015)
Brand name: Nucala
Generic name: mepolizumab
Dosage form: Injection
Treatment for: Asthma, Eosinophilic Granulomatosis with Polyangiitis
Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Development History and FDA Approval Process for Nucala
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.